Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

Why Investors Shouldn’t Pull the Trigger on Moderna Stock Yet

By Larry Ramer, InvestorPlace Contributor

Fears about coronavirus are likely to ease in the coming days and weeks, and there won;t be much news about Moderna's vaccines.

Wait to Buy Lululemon Stock on Likely Post-Earnings Weakness

By Larry Ramer, InvestorPlace Contributor

LULU stock will probably drop after the company reports its Q4 results, but Lululemon continues to have strong, positive catalysts in 2020.

Why MU Stock Looks Attractive for Longer Term Investors

By Larry Ramer, InvestorPlace Contributor

MU stock should be boosted by multiple, positive trends over the longer term,and its valuation is reasonable.

Don’t Hitch a Ride With Virgin Galactic Stock

By Larry Ramer, InvestorPlace Contributor

Investors will probably avoid SPCE stock in the short term. And in the longer term, the company is facing far too many risks.

Remdesivir, Other Positive Catalysts Should Lift Gilead Stock

By Larry Ramer, InvestorPlace Contributor

Remdesivir appears to have helped coronavirus patients, and the drug looks poised to boost GILD stock.

Load More